HC Wainwright Reaffirms Buy Rating for Lisata Therapeutics (NASDAQ:LSTA)

Lisata Therapeutics (NASDAQ:LSTA)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Thursday,Benzinga reports. They presently have a $15.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 410.20% from the stock’s previous close.

Lisata Therapeutics Stock Up 6.9 %

Shares of LSTA stock opened at $2.94 on Thursday. The stock has a market cap of $24.67 million, a P/E ratio of -1.17 and a beta of 1.22. Lisata Therapeutics has a fifty-two week low of $2.05 and a fifty-two week high of $3.83. The business has a fifty day simple moving average of $2.94 and a 200-day simple moving average of $3.09.

Lisata Therapeutics (NASDAQ:LSTA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.16. During the same period last year, the firm posted ($0.65) EPS. On average, sell-side analysts anticipate that Lisata Therapeutics will post -2.84 earnings per share for the current year.

Hedge Funds Weigh In On Lisata Therapeutics

A hedge fund recently raised its stake in Lisata Therapeutics stock. Dimensional Fund Advisors LP lifted its holdings in shares of Lisata Therapeutics, Inc. (NASDAQ:LSTA) by 48.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 17,336 shares of the company’s stock after purchasing an additional 5,639 shares during the quarter. Dimensional Fund Advisors LP owned about 0.21% of Lisata Therapeutics worth $60,000 as of its most recent SEC filing. Institutional investors own 8.94% of the company’s stock.

Lisata Therapeutics Company Profile

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.